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The potential interference in testosterone metabolism through ingested substances has
ramifications for: (i) a range of pathologies such as prostate cancer, (ii) medication contra-
indications, (iii) disruption to the endocrine system, and (iv) potential confounding effects
on doping tests. Conjugation of anabolic steroids during phase II metabolism, mainly dri-
ven by UDP-glucuronosyltransferase (UGT) 2B7, 2B15, and 2B17, has been shown to be
impaired in vitro by a range of compounds including xenobiotics and pharmaceuticals. Fol-
lowing early reports on the effects of a range of xenobiotics on UGT activity in vitro, the
work was extended to reveal similar effects with common non-steroidal anti-inflammatory
drugs. Notably, recent studies have evidenced inhibitory effects of the common foodstuffs
green tea and red wine, along with their constituent flavonoids and catechins. This review
amalgamates the existing evidence for the inhibitory effects of various pharmaceutical and
dietary substances on the rate of UGT glucuronidation of testosterone; and evaluates the
potential consequences for health linked to steroid levels, interaction with treatment drugs
metabolized by the UGT enzyme and steroid abuse in sport.
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INTRODUCTION
As a major route for excretion of exogenous and endogenous
compounds, there is considerable interest in the roles of the
UDP-glucuronosyltransferase (UGT) family, which has led to
widespread investigations of their potential effects in health and
disease (1–4). In particular, genetic and chemical modification
of UGT activity relating to steroid metabolism has ramifications
for a range of pathologies such as prostate cancer, medication
contra-indications,disruption to the endocrine system,and poten-
tial confounding effects on doping tests in sport. Therefore, it is
timely to review lifestyle factors that affect UGT activity. Variations
in the activity of UGT isozymes occur as a result of gender and
ethnic origins giving different levels of expression of UGT forms
and altered ratios of testosterone/epitestosterone excreted in urine
(5). In addition to genetic variations, from a steroid metabolism
viewpoint, one current focus of investigation is on the regulation
of specific UGT activity via induction or inhibition by exogenous
compounds such as pharmaceuticals and dietary components.
Several reports show induction of UGT activity by a range of
compounds including phytochemicals and pharmaceuticals (6–8).
Early studies reported the effects of drugs and dietary compounds
on UGT activity in isolated microsomes or in rats without detailing
the specific UGT isozymes involved (9, 10). Liver microsomal glu-
curonidation of estradiol and estrone was inhibited by green and
black teas, along with a constituent catechin [(-)-epigallocatechin
gallate] and several flavonoids (kaempferol, quercetin, rutin,
flavone, naringenin, hesperetin) (11). Green tea polyphenols had
a strong inhibitory effect of glucuronidation in vitro and showed a
small increase in liver glucuronidation activity against estrone and
estradiol was observed in vitro in rats with green tea as the sole
fluid source (11). Consequent alterations in steroid metabolism
have been debated to have a range of putative effects including
varying responses to doping tests, inter-medication interactions,
and susceptibility to developing cancer (2, 12).
From a treatment perspective, the roles of common com-
pounds, including dietary components have been investigated as
UGT inhibitors with a view to enhancing bioavailability of drugs.
This approach to impairing metabolism and thus increasing the
half-lives of drugs has been the subject of patent protection for a
wide range of drugs (raloxifene, 2-methoxyestradiol, irinotecan,
estradiol, labetalol, dilevalol, zidovudine, and morphine) using
numerous inhibitors from plant origin (epicatechin gallate, epi-
gallocatechin gallate, octyl gallate, propyl gallate, quercetin, tannic
acid, benzoin gum, capsaicin, dihydrocapsaicin, eugenol, gallocat-
echin gallate, geraniol, menthol, menthyl acetate, naringenin, all-
spice berry oil, N -vanillylnonanamide, clovebud oil, peppermint
oil, silibinin, and silymarin) (13). Regulation of UGTs by phyto-
chemicals has been reviewed with a focus on cancer prevention (3).
The aim of this review is to present a critical evaluation of the
current literature on dietary effects on steroid clearance. To date,
the reports have focused on in vitro studies using supersomes,
microsomes, and enzymes model systems, with reports of in vivo
studies with a focus on UGT2B17 are lacking. Thus, it is apposite to
generate a fuller understanding of the role of dietary components
before in vivo studies are undertaken.
PHARMACEUTICAL INHIBITORS OF UGT STEROID
GLUCURONIDATION
Early reports demonstrated that a number of compounds interfere
with the activity of UGT2B17 which is the major isozyme for
clearance of anabolic steroids, having greater than double the
activity of the next most active form UGT2A1. Sten et al.
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FIGURE 1 | Structures of testosterone (1) and selected inhibitors: epicatechin (2), quercetin (3), and epigallocatechin gallate (4).
(14, 15) reported that epitestosterone and two non-steroidal anti-
inflammatory drugs (NSAID) act as competitive inhibitors against
UGT2B17. Using human microsomes and recombinant enzymes
they demonstrated that diclofenac and ibuprofen inhibited testos-
terone glucuronidation without having significant effects on
epitestosterone glucuronidation. Similar inhibitory effects on
testosterone glucuronidation were reported for both UGT2B15
and UGT2B17 isozymes in in vitro studies. The authors measured
IC50 values for diclofenac inhibition of testosterone glucuronida-
tion by UGT2B15 and UGT2B17 of 25µM and 65µM respec-
tively, at testosterone concentrations of 10µM. The corresponding
IC50 values for ibuprofen were 121µM and 1340µM against
UGT2B15 and UGT2B17 respectively. Kinetic experiments using
Dixon plots revealed that the diclofenac acts through competitive
inhibition.
To date, no commensurate studies have been reported demon-
strating an effect of pharmaceuticals on testosterone glucuronida-
tion in vivo. A recent report showed only a slight modification
but no significant effects of concomitant use of maximum recom-
mended doses of ibuprofen or diclofenac with testosterone on the
urinary ratios of testosterone/epitestosterone in individuals with
either two, one, or no allele of the UGT2B17, and no effect when
ibuprofen/diclofenac was administered prior to single dose of
testosterone (16). Given the competitive nature of the inhibition,
at least for diclofenac, the experiment was limited by restriction to
maximum doses of the NSAID. Thus, doses of 50 mg× 3 per day
of the single competitive inhibitor, although well reasoned, may
not elicit an inhibitory effect given that ibuprofen can also elevate
UGT enzyme activity in vivo (8). Although reports of in vivo stud-
ies are lacking to date, the potential effects of inhibiting major
testosterone-metabolizing enzymes warrants further exploration,
especially if common substances are considered where maximum
dosage effects do not limit intake. From one standpoint, this
effect could alter the results of a doping test which is based on
the ratio of the glucuronidated testosterone and epitestosterone.
Following these advances, researchers have recently explored the
effects of dietary components on steroid metabolism. The chemi-
cal structures of testosterone and selected inhibitors are shown in
Figure 1.
DIETARY INHIBITORS OF UGT STEROID GLUCURONIDATION
Given the growing body of literature regarding: (i) key roles for
UGT enzymes in the metabolism a wide range of endogenous
and exogenous compounds, (ii) the increasing understanding of
the specificity UGT isozymes for varying substrates, and (iii)
the roles of many common substances in elevating UGT activ-
ity in vivo and reducing UGT activity in vitro; studies on the roles
of dietary components on testosterone glucuronidation in vitro
were warranted.
Jenkinson et al. (17) first reported the effects of dietary green
and white teas on the activity of UGT2B17 toward testosterone
glucuronidation. Using an high performance liquid chromatogra-
phy (HPLC) assay, testosterone glucuronidation was monitored
in the presence of tea extracts using human UGT2B17 super-
somes. Under the conditions studied, green and white tea prepa-
rations inhibited the reaction by circa 20% with a white tea
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Table 1 | Inhibitory profiles for intact foods and catechins.
Foods Testosterone glucuronidation rate
(ng/mL/min/mg protein)
Testosterone control (12µg/mL) 682.09±30.73
Cacao beans 666.22±23.55
Cacao block 572.89±20.14
White tea beard 249.83±18.87
White tea leaf 246.22±16.61
Green tea 179.56±22.64
White tea powder 69.57±11.04
Catechin (250µM) Testosterone glucuronidation rate
(ng/mL/min/mg protein)
Testosterone control (10µg/mL) 453.77±10.24
Gallocatechin 446.25±37.92
Caffeine 441.25±23.75
Epigallo catechin 420.42±27.08
(−) Epicatechin 352.08±20.42
(+) Epicatechin 264.17±15.83
Epicatechin gallate 143.75±13.75
Epigallocatechin gallate 99.17±19.17
Catechin gallate 70.42±7.92
powder inhibiting glucuronidation by 30%. HPLC analysis of
the teas revealed key constituents such as epicatechin (EC) and
epigallocatechin gallate (EGCG). Analysis via a Dixon plot revealed
that EGCG was acting as a competitive inhibitor with an IC50 value
of 64µM which equaled that found previously for diclofenac (15).
At a concentration of 1 mM, EC inhibited testosterone (at 10µM)
glucuronidation by some 55% (17).
Further studies by the authors, using a different HPLC method,
revealed that cacao also inhibits UGT2B17 but to a lesser extent
(ca. 15%) as shown in Table 1 (18). Under these conditions,
at testosterone concentrations of 12µg/mL, white and green tea
preparations inhibited over 70% of activity with a white tea powder
form showing inhibition of some 90% (Table 1). For the individ-
ual phenolics, inhibition was insignificant for gallocatechin and
caffeine but ranged up to 22 and 42% for (−) epicatechin and (+)
epicatechin respectively (Table 1). As shown in Table 1, extensive
inhibition of testosterone glucuronidation was observed for epi-
catechin gallate (ca. 70%), epigallocatechin gallate (ca. 78%), and
catechin gallate (ca. 90%) (17).
Analysis of the tea and cacao samples by HPLC (17, 18) revealed
the catechins displayed in Table 1 were present in these samples
at lower levels in comparison to the tea samples. The cacao sam-
ples, whilst inhibiting testosterone glucuronidation, did so at a
much lesser rate than the tea samples which could be linked with
having lower levels of inhibiting catechin compounds at the same
concentrations of the tea samples.
In addition, red wine and its constituents were shown to
inhibit testosterone glucuronidation by human UGT2B17 super-
somes (19). Under the conditions studied, red wine inhibited
glucuronidation by up to 70% over a 2-h period, with little
effect arising from the alcohol content. Phenolic components
were selected following HPLC analysis of the selected red wine
and quercetin, caffeic acid, and gallic acid inhibited UGT2B17
testosterone glucuronidation by 72, 22, and 9% respectively, with
concentrations of phenolic:testosterone of 100µM:250µM. For
the most active phenolic, reducing the quercetin concentration to
2µM, maintained inhibition of 20% in spite of the 10-fold excess
of testosterone.
DISCUSSION AND FUTURE DIRECTIONS
Based on the observed effect in vitro, the presence of flavonoids
and catechins in a wide range of foodstuffs points to the poten-
tial for interaction in vivo with UGT2B17 activity. However, to
our knowledge this has yet to be investigated in a clinical set-
ting. Studies have shown oral administration of green tea extract
catechins in rats lead to increased plasma testosterone as well as
elevating other hormones over 8 weeks (20). The short term effects
of iP administration EGCG in rats over 7 days found a number of
hormones in serum dropped including testosterone, however hor-
mone levels remained the same when EC, epigallocatechin (EGC),
and epicatechin-3-gallate (ECG) were administered (21).
Dietary components inhibiting UGT2B17 could have clini-
cal significance in altering the risk for prostate cancer. A recent
review (2) highlights a number of studies that demonstrate an
increase risk of prostate cancer with altered UGT2B17 function,
although in the midst of conflicting evidence,determining the con-
sequence of UGT2B17 polymorphism in prostate cancer risk has
remained inconclusive. In a clinical setting catechins have been
analyzed more for their apoptotic activities on prostate cancer
cells rather than the links between endocrine levels and prostate
cancer (22).
Clearly, the confounding issue of the contrasting effects of ele-
vating enzyme activity, perhaps by induction, and concomitant
chemical inhibition of the enzyme, will require rigorous inves-
tigation. We need to considerably further our knowledge of the
effects of diet on the key UGT isozymes involved in steroid metab-
olism. This includes effects and mechanisms leading to elevation
of enzyme activity but also gaining a full profile of inhibitors.
Given the potential for varied responses in different tissues, the
roles of UGT2B17 inhibitors as endocrine disrupters (23), devel-
oping androgen related pathologies, and in contra-indications to
medicines still warrants full investigation.
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